id,date,date_precision,status,transaction_type,round,amount_usd_low,amount_usd_high,lead_or_buyer,co_leads,valuation_usd_low,valuation_usd_high,valuation_basis,valuation_to_run_rate_multiple,multiple_bound,multiple_basis,step_up_vs_prior_closed,price_per_share_usd_low,price_per_share_usd_high,shares,source,source_url,other_source_urls,notes,last_updated
eckuity-2025-05-16,2025-05-16,day,Closed round,primary_equity,Strategic investment (Eckuity Capital),,,Eckuity Capital,,,,,,,,,,,,"Huma, 16 May 2025",https://www.huma.com/newsroom/huma-announces-partnership-with-eckuity-capital-to-accelerate-m-a-and-acquires-aluna,,Amount not disclosed. Announced together with Huma’s acquisition of Aluna and an M&A-focused partnership.,2026-11-13
series-d-2024-07-16,2024-07-16,day,Closed round,primary_equity,Series D,80000000,80000000,,"With: AstraZeneca, HAT Technology Fund 4, Hitachi Ventures, Leaps by Bayer",,,Bloomberg headline (“near-$1 billion valuation”); not stated by Huma,,,,,,,,"Huma, 16 Jul 2024",https://www.huma.com/newsroom/press-release-series-d-launches-huma-cloud-platform-genai,https://www.bloomberg.com/news/articles/2024-07-16/health-ai-startup-huma-gets-80-million-at-near-1-billion-value,Huma’s “over $80m” share issuance includes strategic investments made since the Series C. $80M is used as a floor.,2026-11-13
series-c-2021-05-11,2021-05-11,day,Closed round,primary_equity,Series C,100000000,100000000,"Leaps by Bayer, Hitachi Ventures","With: Samsung Next, Sony Innovation Fund, Unilever Ventures, HAT and others",,,,,,,,,,,"Huma via PR Newswire, 11 May 2021",https://www.prnewswire.com/news-releases/huma-raises-130-million-financing-to-scale-its-digital-health-platform-for-better-care-and-research-301288726.html,https://techcrunch.com/2021/05/11/huma-which-uses-ai-and-biomarkers-to-monitor-patients-and-for-medical-research-raises-130m/,Announced as ~$130M: $100M equity + $30M credit. A further $70M equity option was agreed but is not counted (exercise not confirmed).,2026-11-13
series-b-2019-11-05,2019-11-05,day,Closed round,primary_equity,Series B (as Medopad),25000000,25000000,Bayer,"With: NWS Holdings, Healthbox",,,Post-money range reported by TechCrunch,,,,,,,,"TechCrunch, 5 Nov 2019",https://techcrunch.com/2019/11/05/medopad-raises-25m-led-by-bayer-to-develop-biomarkers-tracked-via-apps-and-wearables/,,,2026-11-13